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Abstract
Background: Foot-and-mouth disease (FMD) is a highly contagious disease of livestock which causes severe
economic loss in cloven-hoofed animals. Vaccination is still a major strategy in developing countries to control
FMD. Currently, inactivated vaccine of FMDV has been used in many countries with limited success and safety
concerns. Development of a novel effective vaccine is must.
Methods: In the present study, two recombinant pseudotype baculoviruses, one expressing the capsid of foot-
and-mouth disease virus (FMDV) under the control of a cytomegalovirus immediate early enhancer/promoter
(CMV-IE), and the other the caspid plus a T-cell immunogen coding region under a CAG promoter were
constructed, and their expression was characterized in mammalian cells. In addition, their immunogenicity in a
mouse model was investigated. The humoral and cell-mediated immune responses induced by pseudotype
baculovirus were compared with those of inactivated vaccine.
Results: Indirect immunofluorescence assay (IFA) and indirect sandwich-ELISA (IS-ELISA) showed both recombinant
baculoviruses (with or without T-cell epitopes) were transduced efficiently and expressed target proteins in BHK-21
cells. In mice, intramuscular inoculation of recombinants with 1 × 10
9 or 1 × 10
10 PFU/mouse induced the
production of FMDV-specific neutralizing antibodies and gamma interferon (IFN-g). Furthermore, recombinant
baculovirus with T-cell epitopes had better immunogenicity than the recombinant without T-cell epitopes as
demonstrated by significantly enhanced IFN-g production (P < 0.01) and higher neutralizing antibody titer (P <
0.05). Although the inactivated vaccine produced the highest titer of neutralizing antibodies, a lower IFN-g
expression was observed compared to the two recombinant pseudotype baculoviruses.
Conclusions: These results indicate that pseudotype baculovirus-mediated gene delivery could be a alternative
strategy to develop a new generation of vaccines against FMDV infection.
Background
Foot-and-mouth disease (FMD) is a highly contagious
disease of cloven-hoofed animals. The causative agent is
foot-and-mouth disease virus (FMDV) which belongs to
the genus Aphthovirus in the family Picornaviridae [1].
Foot-and-mouth disease is a major hindrance to
international trade in animals and animal products. Pre-
vention and eradication of this disease in one country
requires sustained effort at significant cost. Vaccination
is still a major strategy in developing countries to con-
trol FMD. Current FMDV vaccines are available in the
form of BEI inactivated antigen in oil adjuvant or alumi-
num hydroxide and saponin adjuvant [2]. Although
these vaccines can induce humoral protective immunity,
there are a number of disadvantages with their use,
including the inability to differentiate vaccinated from
unvaccinated animals, the short-term nature of
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required for their preparation, and the risk of escaped
virus [3,4]. Thus, it is crucial to develop alternative
vaccines.
Since Hofmann reported that recombinant baculovirus
containing the cytomegalovirus immediate-early promo-
ter (CMV-IE) was able to drive the expression of a
reporter gene in human hepatocytes, baculovirus with a
strong mammalian promoter has been used as a novel
vector to transfer and express foreign genes in mamma-
lian cells for vaccine development [5-7]. This vector was
also shown to be capable of carrying large inserts and
infecting a variety of cell lines without any apparent
viral replication or cytopathic effects, even at a high
multiplicity of infection (MOI) [7,8]. Furthermore, it has
been reported that a pseudotype baculovirus displaying
the glycoprotein of vesicular stomatitis virus (VSV-G)
on the envelope can extend the host range, increase the
transduction efficiency, and prolong the baculovirus-
mediated expression in mammalian cells [9,10].
The use of baculovirus as a vector for vaccination was
initially described by Aoki and coworkers, who demon-
strated that injecting mice with a recombinant vector
expressing pseudorabies virus glycoprotein B elicited a
measurable humoral response directed against this viral
glycoprotein [11]. More recently, direct vaccination with
recombinant pseudotype baculovirus induced high-level
humoral and cell-mediated immunity against various
antigens such as influenza virus HA [12], porcine repro-
ductive and respiratory syndrome virus (PRRSV) [13],
Japanese encephalitis virus (JEV) [14], porcine circovirus
type 2 (PCV2) [15], Toxoplasma gondii [16], and Plas-
modium falciparum [17].
Although it is generally accepted that protective
immunity to FMDV is principally due to a neutralizing
antibody, a T-cell response is quite clearly necessary for
effective immunity; this was demonstrated in pigs that
showed no consistent humoral immune response after
inoculation with inactivated vaccine but could still resist
virulent virus challenge. It is now believed that cell-
mediated immunity is crucial for protection against
FMD. Helper T (Th) lymphocyte epitopes with con-
served sequences among different FMDV isolates, and
that are recognized by a wide spectrum of MHC Class
II alleles in different host species, hold great potential
for vaccine design. Residues 20-34 in the structural pro-
tein VP4 [18,19] and T-cell epitopes identified on the
FMDV non-structural proteins 3D [20,21] and 3A [18]
are highly interspecies MHC-restricted Th lymphocyte
epitopes. Such epitopes have the additional advantage of
being recognized in a heterotypic manner by T-cells of
different individuals. The potential of such Th epitopes
to improve immunogenicity of a new FMDV vaccine is
an ongoing focus of investigation.
Based on these observations, a T-cell epitope fragment
was designed with two universal T-cell epitopes and sev-
eral conservative T-cell epitopes on the FMDV struc-
tural and non-structural proteins. Two recombinant
pseudotype baculoviruses encoding P12A and 3C, with
or without insertion of the above T-cell epitopes, were
constructed and their expression was characterized in
mammalian cells. In addition, their immunogenicity in a
mouse model was investigated. The humoral and cell-
mediated immune responses induced by pseudotype
baculovirus were compared with those of inactivated
vaccine. The results obtained further demonstrate that
significant cell-mediated immunity to target antigens
can be elicited upon injection of recombinant pseudo-
type baculovirus.
Materials and methods
Virus and cultured cells
O-serotype FMDV (strain O/HN/CHA/93 with high
homology to O/GD/CHA/86, GenBank AJ131468) was
provided by the National Foot-and-Mouth Disease
Reference Laboratory of China to clone the P1-2A and
3C genes of O type FMDV. The BHK-21 cells were
grown and maintained in Dulbecco’s modified Eagle’s
medium (DMEM, Invitrogen) supplemented with 10%
heat-inactivated fetal bovine serum (FBS). Spodoptera
frugiperda 9 (Sf-9) insect cells were maintained at 27°C
in Sf-900 II SFM (Invitrogen) supplemented with 2.5%
fetal bovine serum.
Construction of recombinant pseudotype baculovirus
In order to construct a pseudotype baculovirus, a DNA
fragment was synthesized that contained a coding region
of a truncated VSV-G, a herpes simplex virus-thymidine
kinase (HSV tk) Poly(A) terminal sequence, and a
CMV-IE promoter flanked with BamHIa n dXba I
restriction sites. The truncated VSV-G includes a 21
amino acid ectodomain with transmembrane and cyto-
plasmic tail domains (VSV-GED) as described by Kaik-
konen et al. [22]. The above DNA fragment was
synthesized by GenScript Corporation (Centennial Ave.,
Piscataway, NJ 08854, U.S.) with codon optimization for
expression in insect cells. This DNA fragment was then
inserted into pFastBac Dual vector (Invitrogen) under
the control of the polyhedron (PH) promoter via BamH
Ia n dXba I restriction sites. This vector was designated
pFastBacDual-GED. The DNA fragment containing the
P12A3C expression cassette of O-type FMDV was
inserted into pFastBacDual-GED via Xba Ia n dHind III
restriction sites, resulting in the recombinant transfer
plasmid pFastBacDual-GED-P12A3C (Figure 1).
To express a T-cell epitope region in mammalian cells,
we utilized the CAG promoter, a composite promoter
consisting of the CMV IE enhancer and chicken b-actin
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epitope region (495 bp) were synthesized by GenScript
Corporation and inserted into pFastBacDual-GED-
P12A3C downstream of the p10 promoter followed by the
HSV tk Poly (A) tail. The result was the recombinant
transfer plasmid pFastBacDual-GED-P12A3CT. The T-
cell epitopes synthesized contained two universal immu-
nostimulatory elements and several T-cell epitopes on
structural and non-structural proteins of FMDV (Table 1).
The recombinant baculoviruses Bac-GED, Bac-GED-
P12A3C, and Bac-GED-P12A3CT were subsequently
generated using the Bac-to-Bac System (Invitrogen).
Briefly, the recombinant plasmids were transformed into
Escherichia coli DH10Bac (Invitrogen), in which all the
expression cassettes between Tn7R and Tn7L had been
transferred from pFastBacDual-GED, pFastBacDual-
GED-P12A3C, and pFastBacDual-GED-P12A3CT to the
bacmid by site-specific transposition. The subsequent
steps for bacmid isolation, transfection, and selection of
the recombinant viruses were performed according to
the manufacturer’s instructions for the Bac-to-Bac Sys-
tem. Recombinant baculoviruses were amplified further
by propagation in Sf-9 cells. Virus purification was per-
formed as described previously [23] and purified virus
was resuspended in phosphate-buffered saline (PBS, pH
7.4). The virus titer was determined by the BacPAK
Rapid Titer assay (Clontech, Mountain View, CA, USA)
in Sf-9 cells.
Baculovirus transduction and protein expression assay
The BHK-21 cells were seeded at a concentration of
2.5 × 10
5 cells/well into six-well tissue culture plates
(Nunc) until the cells reached approximately 70-80%
confluence. Culture medium was removed and cells
were washed three times with PBS (pH 7.4). The cells
were then incubated in media containing baculovirus for
6 h at 27°C. After removal of virus, fresh medium was
added and cultures were incubated at 37°C. At 48 h
Figure 1 Schematic diagram of the transfer plasmid for construction of recombinant baculovirus. The structure of the transfer plasmid
based on pFastBac Dual is displayed. pH, polyhedrin promoter of baculovirus; p10, p10 promoter of baculovirus; VSV/GED, truncated
glycoprotein of vesicular stomatitis virus including 21 amino acid ectodomain with transmembrane and cytoplasmic tail domains; CMV,
cytomegalovirus immediate-early promoter/enhancer; SV40 or tk poly (A), polyadenylation signal from Simian virus 40 or tk gene of Herpes
simplex virus; P12A3C, the P12A3C gene encoding structural and non-structural proteins necessary for the formation of FMDV empty capsid;
CAG, a composite promoter consisting of the CMV IE enhancer and chicken b-actin promoter; T-cell epitopes including a pan DR epitope
sequence (PADRE), seven T cell epitope regions in structural or non-structural proteins of FMDV and a invasin immunostimulatory sequence
taken from Yersinia, as described by Wang et al. (2002).
Table 1 T-cell epitopes included in the synthesized T-cell
immunogen
Epitopes Sequence Function
PADRE AKFVAAWTLKAAA TH
VP420-34 SIINNYYMQQYQNSM TH
VP4 62-81 TQNNDWFSKLASSAFSGLFG TH
VP1157-165 RTLPTSFNY Tc
VP126-34 RRQHTDVSF Tc
3A21-35 AAIEFFEGMVHDSIK TH
3D182-201 VDVLPVEHILYTRMMIGRFC TH
3D342-371 VVASDYDLDFEALKPHFKSLGQTITPADKS TH
Invasin TAKSKKFPSYTATYQF TH
The T-cell epitopes were ligated sequentially via two glycines (Gs) as
following: PADRE-GG-VP420-34-GG-VP4 62-81-GG-VP1157-165-GG-VP126-34-GG-3A21-
35-GG-3D182-201-GG-3D342-371-GG- Invasin.
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FMDV proteins by the indirect immunofluorescence
assay (IFA) and indirect sandwich-ELISA (IS-ELISA).
Briefly, cells were fixed with 4% paraformaldehyde and
processed for indirect immunofluorescence assay (IFA)
using rabbit serum against FMDV 146S antigen, fol-
lowed by fluorescein isothiocyanate-conjugated goat
anti-rabbit IgG. The unbound fluorescent antibodies
were washed away with PBST and the cells were sealed
with glycerol and observed under a fluorescence micro-
scope. Indirect sandwich-ELISA was performed as
described previously [24]. Expression of the VSV-GED
protein was monitored in Sf-9 cells by IFA with a rabbit
monoclonal antibody specific for VSV-G (Sigma), and
the recombinant baculovirus Bac-P12A3C constructed
previously was used as a mock-infected control [24].
Immunization of mice
Six to eight weeks old female BALB/c mice, purchased
from the Animal Center, Lanzhou Institute of Biological
Products, Gansu Province, 730046, China, were ran-
domly divided into seven groups with eight mice per
group. Two groups were injected intramuscularly with
1×1 0
9 PFU and 1 × 10
10 PFU of Bac-GED-P12A3C.
Two groups were injected intramuscularly with 1 × 10
9
and 1 × 10
10 PFU of Bac-GED-P12A3CT. The other
three groups were immunized intramuscularly with
1×1 0
10 PFU of Bac-GED, 100 μL of PBS, or 100 μL inac-
tivated vaccine. Booster immunization was performed
identically 3 weeks later. Serum samples were collected
from the retro-orbital plexus at 3 and 7 weeks after
immunization for serological tests. At 7 weeks after the
primary immunization, mice were sacrificed and spleno-
cytes were harvested for IFN-g assay. All animal studies
were approved by the Review Board of Lanzhou Veterin-
ary Research Institute, Chinese Academy of Agricultural
Sciences (Permission number: SYXK-GAN-2004-0005).
The mice in this work were kindly bred during the
experiment and mercy-killed at the end of the experi-
ments to reduce the suffering at the most extent.
Detection of specific neutralizing antibodies against
FMDV
Serum samples were heat-inactivated for 45 min at 56°C
before testing. All sera were analyzed for neutralizing
antibody titers by using a micro-neutralization assay
with monolayers of BHK-21 cells [24]. Double dilutions
of sera were reacted with 100 TCID50 of FMDV O/HN/
CHA/93 at 37°C for 1 h. Cells were then added as indi-
cators of residual infectivity. The microplates were incu-
bated at 37°C for 3 days prior to fixation and staining.
The endpoint titers were calculated as the reciprocal of
the last serum dilution to neutralize 100 TCID50 homo-
logous FMDV in 50% of the wells.
IFN-g release assay
Mouse splenocytes were isolated as described previously
[25]. Splenocytes (1 × 10
6/ml) were cultured in 24-well
plates at 37°C in the presence of 5% CO2,i nt h ep r e -
sence or absence of 20 μg/ml FMDV 146S antigen.
After 20 h incubation, culture supernatant was harvested
and the presence of IFN-g was tested using a commer-
cial mouse IFN-g immunoassay ELISA kit (BD
Bioscience) according to the manufacturer’s instructions.
The concentrations of IFN-g in the samples were deter-
mined from the standard curves.
Statistical analysis
Student’s t-test was used to compare the humoral and
cellular immune responses between the different groups.
P-values of < 0.05 were considered statistically
significant.
Results
Construction and identification of recombinant transfer
plasmid
A schematic diagram of the transfer plasmid for con-
struction of recombinant pseudotype baculovirus is illu-
strated in Figure 1. The recombinant transfer plasmids
pFastBacDual-GED-P12A3C and pFastBacDual-GED-
P12A3CT were confirmed by restriction digestion, PCR,
and sequence analysis, and there were no mutations
introduced in target genes.
For construction of the T-cell immunogen, two
universal T-cell epitopes were chosen, a pan HLA DR-
binding peptide (PADRE) [26] and an invasin immunos-
timulatory sequence taken from Yersinia (Invasin) [27].
Eight conservative T-cell epitopes within the structural
and non-structural proteins of O/HN/CHA/93 FMDV
[28] were linked in tandem by two glycine (G) residues
according to the order in Table 1. The DNA sequence
of the designed T-cell immunogen (as shown in Table
1) was synthesized by GenScript Incorporation (http://
www.genscript.com) according to the most commonly
occurring codons in mammalian cells.
Expression of the target proteins by recombinant
baculoviruses in mammalian cells
To determine whether Bac-GED-P12A3C and Bac-GED-
P12A3CT contain and express the VSV-GED protein,
purified virus was analyzed by IFA with a VSV-GED-
specific monoclonal antibody. Expression of the
VSV-GED protein was detected both in the Bac-GED-
P12A3C (Figure 2A) and Bac-GED-P12A3CT (Figure 2B)
preparation, whereas no VSV-G protein was present in
the Bac-P12A3C viral preparation (Figure 2C).
To investigate the transduction efficacy of recombi-
nant baculoviruses and the level of FMDV capsid pro-
teins expression within mammalian cells, BHK-21 cells
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GED-P12A3CT at a multiplicity of infection (MOI) of
100. An indirect immunofluorescence assay and IS-
ELISA were performed at 48 h post-transduction to
detect the FMDV capsid proteins expressed in BHK-21
cells. As shown in Figure 2D-F, cells transfected with
Bac-GED-P12A3C (Figure 2D) and Bac-GED-P12A3CT
(Figure 2E) emitted bright fluorescence, but no detect-
able fluorescence was observed from cells transduced
with Bac-GED (Figure 2F). Furthermore, the OD of the
harvested cell lysates transfected with Bac-GED-P12A3C
and Bac-GED-P12A3CT decreased with greater dilution,
but no changes were observed in the BHK-21 cell
lysates transfected with Bac-GED (Figure 3).
FMDV-specific neutralizing antibodies elicited by Bac-
GED-P12A3C and Bac-GED-P12A3CT in mice
To determine whether the pseudotype baculovirus
expressed proteins could induce FMDV-specific
humoral immune responses in vivo,B A L B / cm i c ew e r e
immunized intramuscularly with two dosages (1 × 10
10
and 1 × 10
9 PFU/mouse) of Bac-GED-P12A3C and Bac-
GED-P12A3CT, while PBS, Bac-GED, and inactivated
vaccine were used as controls. Foot-and-mouth disease-
specific neutralizing antibodies were monitored at 3 and
7 weeks after the primary immunizations. As shown in
Figure 4, mice immunized with 1 × 10
10 and 1 × 10
9
PFU of Bac-GED-P12A3C developed mean neutralizing
antibody titers of 1:12 and 1:9 at 3 weeks, respectively,
and both increased to 1:27 at 7 weeks after primary
inoculation. Mice immunized with 1 × 10
10 and 1 × 10
9
PFU of Bac-GED-P12A3CT produced mean neutralizing
antibody titers of 1:13 at 3 weeks which further
increased to 1:35 and 1:34 at 7 weeks after primary
inoculation. This was significantly higher than Bac-
GED-P12A3C injected mice (n = 5, P < 0.05). As
expected, sera from mice immunized with Bac-GED or
PBS did not display any neutralizing antibody activity
throughout the entire duration of study. However, the
inactivated vaccine group exhibited a much higher neu-
tralizing antibody titer than any other group (n=5 ,P<
0.01), reaching 1:16 at 3 weeks and 1:64 7 weeks after
primary inoculation (Figure 4).
Cellular immunity elicited by recombinant pseudotype
baculoviruses in mice
To further characterize the cell-mediated immune
responses in mice immunized with Bac-GED-P12A3C and
Figure 2 Detection of the VSV-G protein in baculovirus-infected Sf9 cells (A-C) and FMDV capsid proteins in BHK-21 cells (D-F) by
immunofluorescence. VSV-G proteins were detected in Sf9 cells infected with baculovirus Bac-GED-P12A3C (A), Bac-GED-P12A3CT (B), or Bac-
P12A3C (C) by staining with a monoclonal antibody against VSV-G. FMDV capsid proteins were detected in BHK-21 cells after infection with
baculoviruses Bac-GED-P12A3C (D) and Bac-GED-P12A3CT (E) at 48 h post-infection by reaction with a rabbit serum against FMDV 146S antigen.
No positive reaction was shown in BHK cells transduced with Bac-GED (F).
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mary immunization and IFN-g production in splenocytes
was measured by ELISA after restimulation with FMDV
146S antigen. As shown in Figure 5, mean IFN-g produc-
tion reached 1917 and 1332 pg/ml in mice inoculated with
1×1 0
10 and 1 × 10
9 PFU of Bac-GED-P12A3CT, which
was significantly higher than splenocytes from mice that
received the same two doses of Bac-GED-P12A3C (771
and 813 pg/ml, respectively) or inactivated vaccine (667
pg/ml) (n=3 , P < 0.01). As expected, no significant pro-
duction of IFN-g was detected in PBS-inoculated mice.
But splenocytes harvested from baculovirus Bac-GED
injected mice produced a relatively higher background
non-specific IFN-g response (450 pg/ml).
Figure 3 Detection of protein expression in baculovirus-transduced BHK cells by IS-ELISA. Cell lysates from BHK cells transduced with
baculovirus were prepared at 48 h post-transduction and diluted by two-fold serial dilution. The data are presented as the mean of OD450 for
each dilution.
Figure 4 Neutralizing antibody titers in immunized mice. Neutralizing antibody determinations were performed with sera sampled at
3 and 7 weeks after the primary vaccination. Serum samples were obtained from five mice from each group. Data represent the mean ± SD.
P9, P10 show mice vaccinated with 1 × 10
9 or 1 × 10
10 PFU of Bac-GED-P12A3C; T9, T10 show mice vaccinated with 1 × 10
9 or 1 × 10
10 PFU of
Bac-GED-P12A3CT; “inactivated” denotes mice vaccinated with 100 μL inactivated vaccine.
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Development of a novel vaccine against FMD will have a
significant impact on livestock farming and trade.
A superior immunization protocol should possess
improved immune duration, greater cross protection
between different serotypes and genotypes of FMDV,
and facilitate the differentiation of vaccinated from
infected animals. Recent advances in immunology and
molecular biology have stimulated the development of
gene-based vaccines. The first is based on the use of
plasmid DNA encoding the target antigen of FMDV
[29]. However, the use of plasmid DNA as a gene trans-
fer vehicle for immunization is somewhat limited by the
low transduction efficiency that hampers its immuno-
genic potential. To overcome this problem, live virus
vector-based vaccine is one possible strategy. Recombi-
nant vaccinia virus and adenovirus for expression of
capsid protein has been reported previously [30-32].
Only recombinant adenovirus expressing the empty cap-
sid of FMDV could elicit protective immunity in the
host [33-35]. Swine vaccinated with recombinant adeno-
virus could be protected from virulent virus challenge
even with low titers of neutralizing antibody [36]. In the
study by Sanz-Parra et al. [32], immunized pigs could
d e v e l o pp r o t e c t i v ei m m u n i t yb yF M D V - s p e c i f i cT - c e l l
responses but had no detectable neutralizing antibodies.
These studies indicated lack of neutralizing antibodies
does not necessarily mean absence of protection, at least
in pigs, despite the common belief that humoral
immunity against FMD is the most important factor
determining the efficiency of protection. Thus, the pro-
tection observed in these studies was likely mediated by
the cellular immune response. In addition, some con-
served T-cell epitopes in VP4 and 3A were shown to
induce specific immune responses mediated by CD4
+ T
lymphocytes and B lymphocytes, and the higher Th cell
response could enhance the production of anti-FMDV
neutralizing antibodies [18,37].
Based on these observations, two pseudotype baculo-
viruses, Bac-GED-P12A3C and Bac-GED-P12A3CT,
were constructed to express the empty capsid and a
T-cell immunogen with the expectation that such con-
struction could elicit high levels of anti-FMDV neutra-
lizing antibodies. Among these genes, the P1 sequence
contains important B-lymphocyte and T-lymphocyte
epitopes, allowing stimulation of the cellular and
humoral immune responses, and 3C is a protease neces-
sary for processing of the P12A polyprotein into VP1,
VP3 and VP0, the components of self-assembling empty
capsids. The T-cell immunogen was designed with two
universal T-cell epitopes and several specific T-cell epi-
topes in the structural and non-structural proteins of
FMDV to further enhance the immunogenicity of
recombinant pseudotype baculovirus. Both the humoral
and cellular immune responses were investigated in a
mouse model vaccinated with pseudotype baculoviruses.
All mice immunized with various dosages of Bac-
GED-P12A3C and Bac-GED-P12A3CT developed
Figure 5 IFN-g production in the supernatant of splenocytes harvested from immunized mice after in vitro restimulation. Mice were
immunized as in Figure 4. Splenocytes were isolated 7 weeks after primary immunization and were restimulated in vitro with 146S antigen of
FMDV for 20 h. IFN-g production in the supernatant was analyzed by ELISA. Data represent the mean ± SD. Pos, Neg, or PBS denotes mice
vaccinated with 100 μL inactivated vaccine, 1 × 10
10 PFU of Bac-GED, or 100 μL of PBS.
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P12A3CT infection resulted in a higher antibody
response. This indicated that the involvement of the T-
cell immunogen could enhance the production of anti-
FMDV neutralizing antibodies. However, mice inocu-
lated with inactivated vaccine produced much higher
titers of neutralizing antibodies than Bac-GED-P12A3C
and Bac-GED-P12A3CT, indicating that the amount of
capsid protein expressed by pseudotype baculoviruses
did not reach that in the inactivated vaccine.
In addition to the humoral immune response, cell-
mediated immunity has also been suggested to confer
protective immunity against FMDV [32,38,39]. Host
IFN-g production plays a critical role in directing the
cell-mediated immune responses for the clearance of
intracellular pathogens [40]. Therefore, the production
of IFN-g was measured to evaluate the immunogenicity
of Bac-GED-P12A3C and Bac-GED-P12A3CT in mice.
All mice immunized with various dosages of Bac-
GED-P12A3CT produced much higher levels of IFN-g
than mice infected with Bac-GED-P12A3C, indicating that
insertion of a T-cell immunogen in Bac-GED-P12A3CT
baculovirus could induce a greater cellular immune
responses than Bac-GED-P12A3C. Although inactivated
vaccine could elicit more neutralizing antibody than either
Bac-GED-P12A3C or Bac-GED-P12A3CT, the IFN-g test
demonstrated lower levels of cellular immunity. Indeed,
mice immunized with Bac-GED-P12A3C and Bac-GED-
P12A3CT produced significantly higher levels of IFN-g
compared with mice that received inactivated vaccine. One
possible reason was that baculovirus vectors can not only
transduce mouse skeletal muscle cells, but also efficiently
transduce dendritic cells (DCs), the most important APCs
[17]. The “adjuvant” effect of baculovirus should also be
considered. Baculovirus has the ability to induce innate
immune responses through the Toll-like receptor 9 depen-
dent signaling pathway, resulting in the production of var-
ious cytokines, including tumor necrosis factor-a,I L - 6 ,a n d
interferon [12,23,41,42]. In this study, a higher background
of non-specific IFN-g production was detected from mice
injected with Bac-GED recombinant baculovirus, which
further suggested the presence of the “adjuvant” effect of
baculovirus. A similar result has been observed in pseudo-
type baculovirus expressing PRRSV’s GP5 and M protein
[13], JEV’s E protein [14], PCV2’s ORF2 protein [15], and
Toxoplasma gondii SAG1 protein [16].
Conclusion
In conclusion, Bac-GED-P12A3CT that expressed a T-
cell immunogen and FMDV capsid protein had superior
immunogenicity to Bac-GED-P12A3C that expressed
only the capsid proteins of FMDV, as demonstrated by
enhanced IFN-g production and neutralizing antibody
titer in mice. The combination of caspid protein and
T-cell epitopes in Bac-GED-P12A3CT recombinant
pseudotype baculovirus could be a promising strategy
for the development of a new generation of vaccines
against FMDV.
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